U.S. FDA panel recommends approval of NPS hormone replacement drug

September 12, 2014 9:56 PM

14 0

(Reuters) - A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted 8-5 to recommend approval for Natpara, a hormone replacement therapy developed by NPS Pharmaceuticals Inc.

Shares of NPS, which were halted in regular trading, were down about 1 percent at $32.40 after hours. Since an FDA staff report to the panel was released last week, the shares have gained about 20 percent.

Read more

To category page